Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of California, Irvine Medical Center
mi
from
Orange, CA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of California, Irvine Medical Center
mi
from
Orange, CA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
The Hartford Hospital
mi
from
Hartford, CT
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
The Hospital of Central Connecticut
mi
from
New Britain, CT
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Northside Hospital
mi
from
Atlanta, GA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Women's Cancer Center
mi
from
Covington, LA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Women's Cancer Center
mi
from
Covington, LA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Maryland Greenebaum Cancer Center
mi
from
Baltimore, MD
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Memorial Sloan-Kettering Cancer Institute
mi
from
New York, NY
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Memorial Sloan-Kettering Cancer Institute
mi
from
New York, NY
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Hope Women's Cancer Centers / Mission Hospital, Inc.
mi
from
Asheville, NC
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Hope Women's Cancer Centers / Mission Hospital, Inc.
mi
from
Asheville, NC
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Levine Cancer Institute
mi
from
Charlotte, NC
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
The Ohio State University, Wexner Medical Center
mi
from
Columbus, OH
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Peggy and Charles Oklahoma Cancer Center
mi
from
Oklahoma City, OK
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Peggy and Charles Oklahoma Cancer Center
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Hollings Cancer Center, MUSC
mi
from
Charleston, SC
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Hollings Cancer Center, MUSC
mi
from
Charleston, SC
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Sanford Research/USD
mi
from
Sioux Falls, SD
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Sanford Research/USD
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Inova Fairfax Hospitals
mi
from
Falls Church, VA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Inova Fairfax Hospitals
mi
from
Falls Church, VA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Henrico Doctor's Hospital
mi
from
Richmond, VA
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Henrico Doctor's Hospital
mi
from
Richmond, VA
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Froedtert and the Medical College of Wisconsin
mi
from
Milwaukee, WI
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
University of Colorado
mi
from
Aurora, CO
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
University of Colorado
mi
from
Aurora, CO
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Medizinische Universität Innsbruck
mi
from
Innsbruck,
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Medizinische Universität Innsbruck
mi
from
Innsbruck,
Click here to add this to my saved trials
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated:  12/31/1969
Washington University School of medecine
mi
from
Saint Louis, MO
Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer
Randomized Controlled Study Comparing AEZS-108 With Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer.
Status: Enrolling
Updated: 12/31/1969
Washington University School of medecine
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients
A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
Status: Enrolling
Updated:  12/31/1969
SunCoast CCOP Research Base
mi
from
Tampa, FL
Cluster Randomized Trial Comparing Interventions to Enhance Genetic Counseling Among Breast Cancer Patients
A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics Services Among Breast Cancer Patients
Status: Enrolling
Updated: 12/31/1969
SunCoast CCOP Research Base
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Florida Health Cancer Center
mi
from
Gainesville, FL
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Florida Health Cancer Center
mi
from
Gainesville, FL
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Space Coast Cancer Center
mi
from
Titusville, FL
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Space Coast Cancer Center
mi
from
Titusville, FL
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Florida
mi
from
Weston, FL
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University Cancer and Blood Center LLC
mi
from
Athens, GA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University Cancer and Blood Center LLC
mi
from
Athens, GA
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Augusta University
mi
from
Augusta, GA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Augusta University
mi
from
Augusta, GA
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Illinois Cancer Specialists
mi
from
Arlington Heights, IL
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Illinois Cancer Specialists
mi
from
Arlington Heights, IL
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Illinois Cancer Center
mi
from
Chicago, IL
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Illinois Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Indiana University Health Goshen Center For Cancer Care
mi
from
Goshen, IN
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Iowa Hospitals and Clinics
mi
from
Iowa City, IA
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Eastchester Center for Cancer Care
mi
from
Bronx, NY
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Eastchester Center for Cancer Care
mi
from
Bronx, NY
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Wake Forest Baptist Hospital
mi
from
Winston-Salem, NC
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Wake Forest Baptist Hospital
mi
from
Winston-Salem, NC
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Fairview Hospital
mi
from
Cleveland, OH
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Fairview Hospital
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Taussig Cancer Institute
mi
from
Mayfield Heights, OH
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Taussig Cancer Institute
mi
from
Mayfield Heights, OH
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Bryn Mawr Hospital
mi
from
Bryn Mawr, PA
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
The Pennsylvania State University and Milton s. Hershey Medical Center
mi
from
Hershey, PA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
The Pennsylvania State University and Milton s. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Paoli Hospital
mi
from
Paoli, PA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Paoli Hospital
mi
from
Paoli, PA
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Tennessee Medical Center
mi
from
Knoxville, TN
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Tennessee Medical Center
mi
from
Knoxville, TN
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
University of Virginia
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated:  12/31/1969
Lynchburg Hematology Oncology
mi
from
Lynchburg, VA
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer
A Phase II Double-Blinded, Randomized, Placebo-Controlled Study of Indoximod in Combination With a Taxane Chemotherapy in Metastatic Breast Cancer
Status: Enrolling
Updated: 12/31/1969
Lynchburg Hematology Oncology
mi
from
Lynchburg, VA
Click here to add this to my saved trials